Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study

BACKGROUND: Sars-Cov-2 is a novel corona virus associated with significant morbidity and mortality. Remdesivir and Dexamethasone are two treatments that have shown to be effective against the Sars-Cov-2 associated disease. However, a cost-effectiveness analysis of the two treatments is still lacking...

Descripción completa

Detalles Bibliográficos
Autores principales: Carta, Andrea, Conversano, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449700/
https://www.ncbi.nlm.nih.gov/pubmed/34537034
http://dx.doi.org/10.1186/s12913-021-06998-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449700/
https://www.ncbi.nlm.nih.gov/pubmed/34537034
http://dx.doi.org/10.1186/s12913-021-06998-w

Ejemplares similares